Effect and risk factor of adverse drug events in using dapaglilfozin with type 2 diabetes mellitus patients.

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KIM, Kwi (Seoul National University Hospital, Pharmacy, Seoul, Korea, Republic Of)
  • Co-author(s): Kwi Suk Kim: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Hyung Woo Lee: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Sun Joon Moon: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
    Hee Sim Han: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Eun Jeong Shin: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Jin Hee Baek: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Yoon Sook Cho: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Young Min Cho: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
  • Abstract:

    Background

    US">Dapagliflozin, a selective sodium-glucose co-transporter 2(SGLT2) inhibitor, lowers blood glucose by reducing glucose reabsorption at the proximal renal tubule in an insulin-independent manner.

    Purpose

    US">We aimed to evaluate the efficacy and safety of dapagliflozin and to identify the risk factors of adverse drug events in patients..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login